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Abstract
More than 20 years after the discovery of the hepatitis C virus (HCV), it is now well established that HCV is of global importance
affecting all countries, leading to a major global health problem that requires widespread active interventions for its prevention and con-
trol. Chronic hepatitis C was linked to the development of cirrhosis and hepatocellular carcinoma in many areas of the world. Current
epidemiological assessments have identiﬁed complex patterns with highly variable local prevalence rates between countries and within
countries. HCV infection patterns have not signiﬁcantly changed in most parts of the world since 1997, when ﬁrst analyzed, partly due
to the lack of new and more accurate data. The assessment of the national HCV prevalence and transmission modes should be com-
pleted to enable national authorities to prioritize preventive measures and to make the most appropriate use of available resources.
The ‘patchy’ epidemiological situation in some areas will continue to complicate the task of the establishment of global, regional and
national base line data. The present assessment ﬁnds a global prevalence of 2.35%, affecting 160 million chronically infected individuals.
There is an urgent need for more accurate Information on the costs and burden of HCV to society. Twenty-one year after the discov-
ery of HCV, the assessment is far from being complete and little progress has been made in the past 10 years in many countries. In
some countries signiﬁcant increases have been reported and this may also apply to countries were insufﬁcient data exist. A safe and efﬁ-
cient vaccine against HCV is urgently needed.
Keywords: Epidemiology, HCV, hepatitis C, prevalence, review
Article published online: 22 November 2010
Clin Microbiol Infect 2011; 17: 107–115
Corresponding author: D. Lavanchy, ruelle des Chataigniers 1,
CH-1026 Denges VD, Switzerland
E-mail: lavanchyd@gmail.com
Introduction
After the discovery of the hepatitis C virus (HCV) in 1989
and its linkage to non-A, non-B hepatitis, HCV was ﬁrst
thought to be an infection of minor importance, affecting
selected drug user and blood product recipient populations
in developed countries. More than 20 years later, it is now
well established that HCV is of global importance, affecting
all countries, leading to a major global health problem that
requires widespread active interventions for its prevention
and control. This is no surprise as the spread of HCV (based
on the rate of development of molecular diversity) can be
estimated to date back about 500–2000 years [1].
Chronic hepatitis C has been linked to the development
of hepatocellular carcinoma (HCC) in many areas of the
world. Of the more than 500 000 new cases of liver cancer
that occur each year, 22% (>100 000) are attributable to
HCV infection [2]. Prospective studies have shown that 80%
of cases of acute hepatitis C progress to chronic infection;
10–20% of these will develop complications of chronic liver
disease, such as liver cirrhosis, within two to three decades
of onset, and 1–5% will develop liver cancer [3–7], making
HCV a health problem of global importance [8]. Heavy alco-
hol consumption, particularly in females, age and HCV/human
immunodeﬁciency virus (HIV) co-infection may be associated
with more rapid progression of HCV liver disease, especially
ﬁbrosis [9]. Additional prospective longitudinal studies are
needed to determine whether other factors, such as schisto-
somiasis and clonorchiasis, and exposure to toxic solvents, a
common occurrence in developing countries, are associated
with disease progression. There is an urgent need for more
accurate information on the long-term outcome, with its
consequences for, and costs and burden , to, society.
Transmission
There are still large gaps in our knowledge of the global epi-
demiology of HCV. The relative contributions of the various
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sources of infection have rarely been investigated in popula-
tion-based epidemiological studies in most geographical
areas. The assessment of national HCV prevalence and trans-
mission modes should be completed to enable national
authorities to prioritize preventive measures and to make
the most appropriate use of available resources. In addition,
many unanswered questions exist concerning the roles of
risk factors and lifestyle conditions that may be associated
with HCV spread in different regions of the world. Epidemi-
ological studies on the roles of potential risk factors, such as
medical procedures, injections for medications and immuni-
zations, injections applied outside of medical settings, tattoo-
ing, and scariﬁcation techniques, have shown wide
geographical variations with major implications for local pop-
ulations and potential prevention and control programmes.
As HCV can be sexually transmitted (albeit rarely between
healthy individuals), the role of co-infection with other sexually
transmitted diseases, such as HIV/AIDS, need to be further
studied, especially for those that can result in open genital
sores, such as chlamydial infection, chancroid and syphilis.
Hepatitis C Global Prevalence
HCV has been shown to have a worldwide distribution,
occurring among persons of all ages, genders, races and
regions of the world. The socio-economic burden of HCV
has not yet been deﬁned in most countries. Where the epi-
demiology of hepatitis C has been studied, the consequences
of chronic hepatitis C, HCC and end-stage liver cirrhosis
have been shown to increasingly impact on national health
systems [10]. New infections still occur, because of the con-
tinued use of unscreened or inappropriately screened blood
transfusions and blood products, the failure to sterilize medi-
cal equipment adequately, and the increase in intravenous
drug use in previously unaffected areas. Global, regional and
national monitoring will be necessary to evaluate results and
address shortcomings. The quality and coverage of popula-
tion-based HCV prevalence should be improved, by using: (i)
a representative population sample; and (ii) accurate diagnos-
tic tests. To better evaluate the incidence trends and burden
of chronic disease, the prevalence of HCV infection should
be stratiﬁed according to age, ethnicity and gender. Since
the ﬁrst publication in 1997 [8], published evidence for the
prevalence of HCV still remains disappointedly limited, as
information is still inadequate in many countries, most pub-
lished prevalence studies being of limited scope, representing
only a segment of the population [11–13] (e.g. pregnant
women, blood donors or hospital admissions), with only a
few studies using sampling techniques that represent the
entire population.
Prevalence of hepatitis C worldwide
As most acute HCV infections (60–70%) are asymptomatic
[14–16], data on the incidence of new cases of HCV infec-
tion are difﬁcult to obtain and therefore scarce. Some risk
groups, such as haemophiliacs, haemodialysis patients,
patients transfused with unscreened blood and unscreened
blood products, inmates of long-term correctional facilities,
and persons with occupational exposure, clearly have a high
incidence and prevalence of HCV infection [17–24].
As measurement of incidence fails to produce reliable
numbers, because of the mostly asymptomatic form of acute
infection, most approximations are based on reviews of pub-
lished prevalence data, which estimated that 130–170 million
persons, or 2–3% of the world’s population, are infected
with HCV [25–27]. The current estimates are given in Fig. 1
and Tables 1 and 2. Prevalence estimates are 400 000 chron-
FIG. 1. Hepatitis C global prevalence 2010 (%).
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TABLE 1. Hepatitis C global prevalence country data 2010a
Country Anti-HCV (%) No. infected
Afghanistan 0.5 147 735
Albania 1.5 53 172
Algeria 0.2 70 846
Angola 5 950 000
Antigua and Barbuda 0.75 525
Argentina 1.9 743 750
Armenia 4 133 012
Australia 1.1 227 831
Austria 1 81 748
Azerbaijan 4 314 735
Bahamas 0.75 2250
Bahrain 1.8 12 240
Bangladesh 0.6 986 550
Barbados 0.75 2100
Belarus 2.2 226 600
Belgium 0.9 93 134
Belize 0.75 2100
Benin 1.6 147 392
Bhutan 1.3 28 412
Bolivia 4.7 471 457
Bosnia and Herzegovina 1.5 58 605
Botswana 1.6 31 648
Brazil 1.4 2 609 670
Brunei 2.9 10 846
Bulgaria 1.8 139 068
Burkina Faso 5.2 846 924
Burundi 11.3 888 067
Cambodia 4.1 617 173
Cameroon 13.8 2 754 204
Canada 1 322 680
Cape Verde 3 15 390
Central African Republic 2.4 108 144
Chad 5 575 300
Chile 0.85 134 530
China 2.2 29 791 212
Colombia 0.97 425 191
Comoros 1 7980
Congo 5.5 206 745
Cook Islands 1.5 270
Costa Rica 0.75 32 453
Croatia 1.5 68 265
Cuba 1.8 202 842
Cyprus 0.5 4175
Czech Republic 1.5 153 300
Denmark 0.5 27 155
Djibouti 0.3 2637
Dominica 0.75 593
Dominican Republic 0.75 66 713
Democratic Republic of Congo 6.4 4 010 240
Ecuador 1.4 195 605
Egypt 14 11 826 360
El Salvador 2.5 164 689
Equatorial Guinea 1.7 11 781
Eritrea 1.9 85 500
Estonia 5 70 097
Ethiopia 1.9 1 500 734
Federal States of Micronesia 2 2200
Fiji 2 16 960
Finland 0.5 26 245
France 1.3 814 281
Gabon 9.2 138 092
Georgia 6.7 328 945
Germany 0.75 620 168
Ghana 1.7 413 661
Greece 1.5 166 800
Greenland 0.5 280
Grenada 5 5150
Guatemala 0.8 115 016
Guinea 5.5 567 820
Guinea-Bissau 4.7 77 409
Guyana 0.75 5633
Haiti 4.4 448 272
Honduras 0.5 36 025
Hungary 2.2 219 582
Iceland 0.5 1500
India 1.5 18 216 960
Indonesia 3.9 9 436 986
Iran 0.9 630 450
Iraq 3.21 834 600
Ireland 1.1 44 682
TABLE 1. (Continued)
Country Anti-HCV (%) No. infected
Israel 1 70 000
Italy 3.2 1 923 136
Ivory Coast 3.3 717 783
Jamaica 0.75 20 250
Japan 2.4 3 058 008
Jordan 2.1 114 660
Kazakhstan 3.2 474 592
Kenya 0.9 367 767
Kiribati 2 2020
Kuwait 3.1 68 634
Kyrgyzstan 4 205 880
Laos 1.1 70 796
Latvia 2.2 50 732
Lebanon 0.7 31 850
Lesotho 1 22 660
Liberia 3 123 060
Libya 1.6 104 736
Lithuania 2.2 75 086
Luxembourg 1 4630
Macedonia 2 40 800
Madagascar 1.7 342 482
Malawi 6.8 1 067 056
Malaysia 1.5 397 515
Maldives 1 2850
Mali 3.3 439 659
Malta 1 4000
Marshall Islands 1.5 900
Mauritania 1.1 37 026
Mauritius 2.1 27 237
Mexico 1 1 106 450
Moldova 2.3 99 498
Mongolia 10.7 303 048
Morocco 1.93 624 953
Mozambique 3.2 748 992
Myanmar 1 505 190
Namibia 0.9 19 908
Nauru 2 256
Nepal 0.64 181 037
New Zealand 0.3 11 820
Nicaragua 0.35 19 803
Niger 3.2 50 851
Nigeria 2.1 3 323 439
Niue 2 30
North Korea 1 231 130
Norway 0.55 25 328
Oman 1.2 34 836
Paciﬁc Islands (Palau) 2 606
Pakistan 5.9 9 422 403
Panama 0.75 22 500
Papua New Guinea 2 117 740
Paraguay 1.23 76 162
Peru 1 284 100
Philippines 2.2 1 932 854
Poland 2 770 360
Portugal 1 105 240
Qatar 1.8 15 120
Reunion 0.14 1172
Romania 4.5 1 003 680
Russia 4.1 5 796 498
Rwanda 4.9 452 466
Samoa 0.75 1875
Sao Tome and Principe 10 17 580
Saudi Arabia 1.8 437 292
Senegal 3 385 830
Serbia 1.5 156 345
Seychelles 0.34 289
Sierra Leone 2 117 680
Singapore 1 46 090
Slovakia 1 54 240
Slovenia 1 19 980
Solomon Islands 2 9560
Somalia 1 83 040
South Africa 1.7 858 364
South Korea 1.68 823 956
Spain 2 906 340
Sri Lanka 1 207 180
St Kitts and Nevis 2.2 880
St Lucia 0.75 1232
St Vincent and the Grenadines 1 1180
Sudan 2.8 1 209 376
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ically infected subjects in Australia and Oceania, 14 million in
the Americas, 16 million in the Middle East, 17.5 million in
Europe, 28 million in Africa, and 83 million in Asia [12].
The published data suggest that most populations in the
Americas, western Europe and Southeast Asia have preva-
lence rates of antibody to HCV (anti-HCV) under 2.5%.
Anti-HCV prevalence rates for eastern Europe average from
1.5% to 5%, those for the Western Paciﬁc region from 2.5%
to 4.9%, and those for the Middle East and Central Asia from
1% to more than 12% [27]. In terms of absolute numbers,
the majority of infected people live in Central/Southeast Asia
and the Western Paciﬁc regions (Table 2), a ﬁnding similar
to that for chronic hepatitis B infection.
Only a few studies on cost estimates are available. In the
USA, the current estimate of the annual costs of acute and
chronic hepatitis C exceeds US$600 million [29], and over
the period 2010–2019, the total costs are expected to be
US$184 billion [30], giving an indication of how important
the burden of chronic HCV infection can be for national
health systems, even in a low-endemicity country (1.8%). The
European Monitoring Centre for Drugs and Drug Addiction
estimated the HCV-related costs in ten European Union
countries to be €50 million, excluding HCV drug therapy and
monitoring, thereby demonstrating that, even with no public
health action, HCV causes signiﬁcant costs to society. The
estimates for Spain were approximately €3 billion for the
period 2010–2030 [31], and in Canada the costs are esti-
mated at CD$150 million annually until 2040 [32].
Epidemiological trends
As representative prevalence data are still not available from
many countries, and progress since 1997 has been scarce,
the local, national and regional baseline estimates of the rate
of infection, the number of individuals chronically infected
and the burden of disease are not established, making it
impossible to assess correctly the impact of control and pre-
vention measures. In addition, highly signiﬁcant differences in
subnational population groups have been documented.
For instance, in China, Bao et al. [33] found that the prev-
alence in non-injection drug users varied from 0% (Anhui) to
40.00% (Fujian). Intravenous drug use is increasing in China,
posing a new challenge to public health authorities for the
implementation of harm reduction programmes [34]. Only a
few studies have addressed the prevalence of HCV in China.
In a cross-sectional study conducted in six different regions
of the country, the overall prevalence of HCV was 0.58%,
which was much lower than the 2.7% estimated by the
WHO [35]. On the other hand, the prevalence in the gen-
eral population was found to be 2.1% in Fujian province [36],
9.6% in Henan province [37] and 25% in a rural community
of elderly people [38]. Therefore, in China, the geographical
distribution of HCV infection is heterogeneous, and patterns
differ between rural and urban settings, but, with the signiﬁ-
cant increase in intravenous drug use, it is expected that the
prevalence will generally increase in China.
Hepatitis C is an emerging infection in India as well, and is
already responsible for a signiﬁcant proportion of liver dis-
ease in various states. However, the prevalence appears to
be highly variable (‘patchy’), according to the geographical
site or the population group analysed (0.09–7.89%) [39].
Most of the studies of prevalence have been conducted in
blood banks, and have shown prevalence rates of <2%, but
in professional donors prevalence rates between 55.3% and
87.3% have been found. The consequences of chronic HCV
infection will probably be signiﬁcant increases in morbidity
and mortality in India in the years to come.
TABLE 1. (Continued)
Country Anti-HCV (%) No. infected
Suriname 0.75 3278
Swaziland 1.5 18 030
Sweden 0.5 46 465
Switzerland 1 74 190
Syria 0.5 94 405
Tajikistan 4 292 840
Thailand 2.2 1 499 058
The Gambia 2.4 42 024
The Netherlands 1 163 360
Togo 3.3 223 740
Tonga 2 2200
Trinidad and Tobago 3.9 50 583
Tunisia 1.2 124 488
Turkey 2.2 1 549 108
Turkmenistan 4 268 960
Tuvalu 2 220
Uganda 6.6 2 230 536
UK 1.1 659 032
Ukraine 4 1 864 840
United Arab Emirates 2.3 81 052
United Republic of Tanzania 3.2 1 441 280
Uruguay 1 34 000
USA 1.8 5 367 834
Uzbekistan 6.5 1 774 955
Vanuatu 2 4060
Venezuela 0.94 272 976
Vietnam 1 835 360
Western Sahara 3 15 900
Western Samoa 2 3540
Yemen 1.7 412 352
Montenegro 1.5 10 980
Zambia 1.5 198 855
Zimbabwe 2 262 400
Total infected 158 910 617
% population 2.35
aBased on published data.
TABLE 2. Hepatitis C regional prevalence 2010
Region Anti-HCV (%) No. HCV-infected
Africa 3.2 28 100 000
Americas 1.5 14 000 000
Asia 2.1 83 000 000
Australia and Oceania 1.2 400 000
Europe 2.3 17 500 000
Middle East 4.7 16 000 000
Total 2.35 159 000 000
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Changing trends in HCV over the past 50 years have also
been observed in Japan, where 70% of cases of HCC are
attributable to HCV, and HCC is the fourth leading cause of
death in males and the ﬁfth in females. HCV started to spread
in the 1930s among intravenous drug users (amphetamines)
before, during and after World War II, or through medical
procedures such as blood transfusion and the use of contami-
nated syringes. The prevalence of HCV infection is much
lower in the younger generation than in the older generation
aged >55 years (0.1–0.2% vs. >2%) [40]. Therefore, the total
number of patients with HCV infection is considered to have
decreased. The incidence of HCC has steadily increased over
the last 50 years, but it is now decreasing in Japan, mainly
because of the decreased prevalence of HCV-related HCC. A
similar trend has been observed in Italy [41,42].
Pakistan is a developing country of 170 million people, and
recent investigations have shown that about 10 million
(5.9%) people are presumed to be infected with HCV [43].
Public health authorities are raising awareness about viral
hepatitis among healthcare workers and the general popula-
tion, but tremendous efforts are still required to combat var-
ious risk factors involved in HCV transmission, particularly
because of the non-implementation of international standards
regarding blood transfusion and safe injection practices.
Egypt has a very high prevalence of HCV, reaching as
much as 32% in the population of young males requesting
visas for foreign travel [44–47], and the country suffers high
morbidity and mortality from chronic liver disease, cirrhosis
and HCC. Approximately 20% of Egyptian blood donors are
anti-HCV-positive [44]. Geographically, the desert areas of
Egypt have the lowest rates of anti-HCV positivity; rural
areas tend to have higher rates than cities; and rates in the
Nile Delta (Lower Egypt) are higher than in the Nile Valley
(Middle Egypt and Upper Egypt) [44,46,47]. The strong
homogeneity of HCV subtypes found in Egypt (mostly 4a)
[48–50] suggests an epidemic spread of HCV [49]. The risk
factor(s) originally responsible for the establishment of HCV
in the general population may not necessarily be the same as
those responsible for transmitting the virus today. Therefore,
both traditional risk factors and risk factors that may be
unique to Egypt need to be considered in explaining the
transmission of HCV in this country. The prime candidate to
explain the high prevalence of HCV in Egypt is the past prac-
tice of parenteral therapy for schistosomiasis with tartar
emetic (potassium antimony tartrate), and the data suggest
that Egypt’s mass campaigns do indeed represent the world’s
largest example of iatrogenic transmission of a blood-borne
pathogen [51]; the large reservoir of chronic HCV infection
established in the course of these campaigns remains the
most likely reason for today’s high prevalence of HCV, which
may be largely responsible for the continuing endemic trans-
mission of HCV today [52]. Egypt has a unique HCV preva-
lence pattern that is not comparable with those of its
eastern Mediterranean neighbours. However, in the recent
past, intravenous drug use has been shown to have increased
in the Middle East, as documented for Iran [53]. It is there-
fore expected that the prevalence of HCV will increase in
the next 10 years.
For Africa, HCV prevalence data are incomplete, but show
considerable variation from one population studied to
another, with prevalence rates from 0% to 51% [54–57].
More than 28 million people are chronically infected with
HCV on this continent. It is currently difﬁcult to determine
trends concerning current and future infection rates.
In Europe, too, the HCV prevalence data are often incom-
plete, outdated or inconclusive. The current estimates are
that 7.3–8.8 million people (1.1–1.3%) are chronically infected
in the European Union, a ﬁgure that is almost double the
ﬁrst estimates performed in 1997 [27], indicating that HCV is
also a major health problem in Europe [58], and an increase
is forecasted for the next decade [59–61]. For the whole of the
European continent, it is estimated that 17.5 million individu-
als are infected. Recently, a 3-month pilot study carried out
by the Hepatitis C Trust in pharmacies in England found that
the prevalence of HCV infection was almost four times as
high as previously estimated. The pilot study found a preva-
lence of 15%, which is signiﬁcantly more than the 4% deter-
mined by tests carried out in general practitioner surgeries in
2008 [62], emphasizing that the study design has major con-
sequences for outcomes in population-based studies, and call-
ing for caution when evaluating published HCV prevalence
ﬁgures, even in well-studied countries.
In addition to anti-HCV-based prevalence studies, longitu-
dinal genotype observation adds a further tool for monitor-
ing epidemiological trends. Measurement of the spatial
introduction of new genotypes in a population, and the rate
of sequence evolution or natural recombinations in viruses
introduced at a given time in a cohort, provides the possibil-
ity of evaluating the history of the past geographical spread
of HCV through different populations, shedding light on the
demographic, social and biological factors that are at the
basis of ancient and current unrecognized routes of transmis-
sion. Genotypes 1–3 have a worldwide distribution [48,63–
65]. Genotypes 4 and 5 are found principally in Africa, and
genotype 6 is distributed in Asia [66]. Endemic areas for spe-
ciﬁc genotypes are found in West Africa (types 1 and 2),
West Central Africa (type 4), the Indian subcontinent
(type 3), Central Africa (type 4) and Southeast Asia (type 6).
An endemic area for genotype 5 has not been found [49,67–
73], except for a local county in central France, where
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HCV 5a contamination of the local population was associated
with living in a rural area called Vic-le-Comte. Abergel et al.
suggest that HCV 5a spread by an iatrogenic route before
1972, and then via transfusion to the whole county [74].
When a limited diversity of HCV subtypes is found in a cer-
tain geographical area, it may be attributed to the recent
introduction of HCV into the population, as was docu-
mented for Canada [75] or Australia [76]. The molecular
epidemiology of HCV genotype 2 points to West and Cen-
tral Africa, mostly along the African Atlantic coast, as its
endemic place of origin. Markov et al. have found an east-
wards spread from the West African coast to Cameroon
that took place over several centuries [77]. Molecular clock
analysis dates the common ancestor of HCV to Guinea-
Bissau, around 1470 (1414–1582). Isolates from Madagascar
and Martinique suggest that the historical slave trade and the
possible parenteral HCV exposure during public health cam-
paigns undertaken during the colonial era may have played a
role in the dissemination of HCV genotypes 2a and 2c. In
summary, the geographical distribution of HCV genotypes
and the rate of genetic variation are consistent with the
global distribution of HCV, and are compatible with a long
history of infection in most populations of the world, pre-
ceding, in many geographical locations, the era of modern
medicine by many centuries.
HCV-related cirrhosis and deaths from HCC are likely to
increase dramatically within the next decade, e.g. in Australia
[78,79], Canada [80], France [81], the UK [59–61] and the
USA [82]. Owing to the increase in intravenous drug use in
China, India and the Middle East, increases are likely to
occur within this decade in these regions too, and because
China and India are the countries with the largest popula-
tions, a 1% increase in both would result in an additional
25 million HCV-infected subjects. If patients are left undiag-
nosed and untreated, the future burden of the disease for
healthcare resources and society will be substantial. A declin-
ing burden in the years to come is expected only in Italy
[42,83], Japan [84], South Korea [84] (accompanied by a
decrease in the incidence of HCC in these two countries)
[85] and the USA [86].
Strategies for Prevention in Light of the
Undetermined Epidemiology
HCV-prevention programmes are needed at the local,
national, regional and global levels if the spread of HCV and
the burden of hepatitis C are to be reduced. To achieve
these objectives, the implementation of measures that reduce
the risk of contracting HCV infection is required, a task that
was unfulﬁlled in many areas in 2010. Such programmes need
to ensure that blood supplies and related products are free
of infection, and that safe injection methods are practised
within and outside medical settings. The use of disposable
syringes for immunization and injections is particularly crucial
in developing countries. Risk-education counselling for pro-
fessionals and the public is of paramount importance. Where
this is affordable, persons with chronic hepatitis C should be
identiﬁed and targeted for special counselling and medical
management, in order to reduce the risk of them developing
HCV-related disease complications. Healthcare professionals
and the public, who are crucial for the effective prevention
of HCV transmission, should be educated about the risk of
transmission of blood-borne pathogens (HCV, hepatitis B
virus and HIV) by contaminated injection and other medical
equipment, as well as by traditional and folk medical proce-
dures or practices [87–89], and should receive appropriate
education and training concerning the importance of control-
ling such infections in all medical, surgical and dental facilities,
including the use of standard precautions, safe injection prac-
tices, proper sterilization techniques, and high-level disinfec-
tion where appropriate, avoiding the re-use and sharing of
contaminated equipment and supplies, and avoiding contami-
nation of multi-use supplies, such as medication vials. The use
of devices or products that prevent re-use or contamination
of medical and dental equipment should be encouraged (e.g.
autodestruct syringes), noting that cost-effective devices are
available [90–92].
Conclusions
From the above, it can be seen that the assessment of the
national, regional and global prevalence of chronic HCV rep-
resents an enormous task that may never be fully achieved.
The ‘patchy’ epidemiological situation in some areas will con-
tinue to complicate the task of the establishment of global,
regional and national baseline data, and this will also apply to
the use of modelling that is currently undertaken by the
CDC and by others. Therefore, new and inventive method-
ologies may have to be applied in order to estimate the
actual baseline of the HCV epidemic and to evaluate future
prevention and control activities. There is a need for better
public awareness, coordinated national and regional action
plans, and better data that take into account representative
population samples. Improved assessment of risk factors in
high-risk groups, the different genders and ‘forgotten’ ethnic
groups is needed. Education should be culturally appropriate
and address the concerns of all populations with HCV.
Twenty-one years after the discovery of HCV, the assess-
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ment is far from being complete, and little progress has been
made in the past 10 years in many countries. The global ﬁg-
ures have not changed signiﬁcantly, with a global estimate of
160 million infected people and a global prevalence of 2.35%
(Tables 1 and 2). However, in some countries, signiﬁcant
increases have been reported, and this may also apply to
countries where insufﬁcient data exist.
Physicians, healthcare workers and public health ofﬁcials
should be aware—and many are not—that many subjects are
unaware of their infections, provide timely testing and antivi-
ral treatment when needed, and avoid further iatrogenic
transmission. It is a public health responsibility to ensure that
prevention and control measures, in particular drug treat-
ment, should be accompanied by the appropriate assessment
and monitoring, using inventive and locally adapted method-
ologies for the evaluation of the baseline and the follow-up
activities. Targeted populations should have equitable access
to care and guaranteed, sustained supplies of medications, as
well as clinical monitoring. Needless to say, in today’s con-
text a safe and efﬁcient vaccine against HCV is urgently
needed, and even a vaccine with suboptimal efﬁciency will
probably help to better control HCV.
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